Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28589992 | 0.84 | LMNA (0.48) | GABBR2GABBR1LMNAL3MBTL1TDP1 | |
| E968 SCHEMBL31315354 | 0.82 | LMNA (0.47) | LMNAL3MBTL1TDP1KDM4EMMP2 | |
| E968 SCHEMBL20559013 | 0.82 | LMNA (0.47) | LMNAL3MBTL1TDP1KDM4EMMP2 | |
| E968 SCHEMBL29038531 | 0.79 | LMNA (0.44) | LMNAL3MBTL1TDP1KDM4EMMP2 | |
| E968 SCHEMBL5481653 | 0.77 | LMNA (0.42) | GABBR2GABBR1LMNAL3MBTL1TDP1 | |
| E968 SCHEMBL25298465 | 0.74 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4ETHRB | |
| E968 SCHEMBL27767182 | 0.74 | — | — | |
| SCHEMBL88028 | 0.74 | LMNA (0.40) | LMNAL3MBTL1TDP1KDM4EMMP2 | |
| SCHEMBL20471 | 0.74 | — | — | |
| SCHEMBL6892726 | 0.74 | LMNA (0.40) | LMNAL3MBTL1TDP1KDM4EMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2992334-B1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2018-06-27 | — | — | EP | claimed |
| EP-2992334-B1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2018-06-27 | — | — | EP | disclosed |
| US-9784701-B2 | Phosphatidylalkanols and compositions thereof | Pethmark AB (SE) | 2017-10-10 | — | — | US | disclosed |
| US-20170052132-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2017-02-23 | — | — | US | disclosed |
| US-9499572-B2 | Phosphatidylalkanols and compositions thereof | Pethmark AB (SE) | 2016-11-22 | — | — | US | disclosed |
| EP-2992334-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | PEthmark AB (SE) | 2016-03-09 | — | — | EP | disclosed |
| US-20160052946-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2016-02-25 | — | — | US | disclosed |
| WO-2014178787-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | Pethmark AB (SE) | 2014-11-06 | — | — | WO | disclosed |
| US-5384406-A | Hydrolysis resistant; agriculture chemical anions | ISP INVESTMENTS INC. (US) | 1995-01-24 | — | — | US | disclosed |
| US-5221791-A | Hydrolysis resistant | ISP INVESTMENTS INC. (US) | 1993-06-22 | — | — | US | disclosed |
| WO-1992021656-A1 | WATER-SOLUBLE BIOLOGICALLY ACTIVE AMMONIUM SALTS | ISP INVESTMENTS INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052946-A1 | NOVEL PHOSPHATIDYLALKANOLS AND COMPOSITIONS THEREOF | PHOSPHO1, SGMS1, DEGS1 | GABBR2 3777/4885GABBR1 4198/4885LMNA 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.